The recombinant influenza vaccine (RIV) is a type of influenza vaccine that is produced using recombinant DNA technology. Unlike traditional flu vaccines, which are typically produced using chicken eggs or cell-based culture methods, RIV leverages genetic engineering to produce the hemagglutinin (HA) protein, which is the primary antigenic component that triggers an immune response in humans.
